305 related articles for article (PubMed ID: 29408752)
1. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
Badiani B; Chiumente M; Messori A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():84-88. PubMed ID: 29408752
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.
Nagy B; Timár G; Józwiak-Hagymásy J; Kovács G; Merész G; Vámossy I; Ágh T; László Á; Vokó Z; Kaló Z
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():75-81. PubMed ID: 24568866
[TBL] [Abstract][Full Text] [Related]
3. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
Fernandez H; Schmidt T; Powell M; Costa AP; Arriagada P; Thaler C
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():91-96. PubMed ID: 27898340
[TBL] [Abstract][Full Text] [Related]
4. Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation.
Maratea D
Minerva Ginecol; 2016 Feb; 68(1):15-20. PubMed ID: 26990098
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
6. Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: a cost-utility analysis.
You JH; Sahota DS; Yuen PM
Fertil Steril; 2009 Feb; 91(2):580-8. PubMed ID: 18295216
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.
Zakiyah N; van Asselt AD; Postma MJ
J Med Econ; 2017 Mar; 20(3):280-287. PubMed ID: 27786570
[TBL] [Abstract][Full Text] [Related]
8. A randomised trial of treating fibroids with either embolisation or myomectomy to measure the effect on quality of life among women wishing to avoid hysterectomy (the FEMME study): study protocol for a randomised controlled trial.
McPherson K; Manyonda I; Lumsden MA; Belli AM; Moss J; Wu O; Middleton L; Daniels J
Trials; 2014 Nov; 15():468. PubMed ID: 25432688
[TBL] [Abstract][Full Text] [Related]
9. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
10. Uterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost-utility analysis of the FEMME trial.
Rana D; Wu O; Cheed V; Middleton LJ; Moss J; Lumsden MA; McKinnon W; Daniels J; Sirkeci F; Manyonda I; Belli AM; McPherson K;
BJOG; 2021 Oct; 128(11):1793-1802. PubMed ID: 34053154
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of pre-operative gonadotrophin releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy.
Farquhar C; Brown PM; Furness S
BJOG; 2002 Nov; 109(11):1273-80. PubMed ID: 12452466
[TBL] [Abstract][Full Text] [Related]
14. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
15. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
[TBL] [Abstract][Full Text] [Related]
16. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
17. A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial.
Middelkoop MA; Huirne JAF; van der Weide MCJ; Bosmans JE; Hehenkamp WJK;
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():63-69. PubMed ID: 33171419
[TBL] [Abstract][Full Text] [Related]
18. Uterine Fibroids: Burden and Unmet Medical Need.
Al-Hendy A; Myers ER; Stewart E
Semin Reprod Med; 2017 Nov; 35(6):473-480. PubMed ID: 29100234
[TBL] [Abstract][Full Text] [Related]
19. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Kadhel P; Smail M; Borja De Mozota D
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):609-611. PubMed ID: 28647614
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis.
Babashov V; Palimaka S; Blackhouse G; O'Reilly D
Ont Health Technol Assess Ser; 2015; 15(5):1-61. PubMed ID: 26357531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
